Company Overview and News

9
Mastercard, Wirecard Pair Up for Payment Via Wearables

7m zacks
Mastercard Incorporated (MA - Free Report) and Wirecard recently announced their agreement to boost the current strategic cooperation with the purpose of making digital, contactless payments through wearables accessible to customers. This collaboration between the global innovation leader of digital financial technology and the international technology company for payment transactions will allow its users to make mobile transactions without the mediation of their bank.
V EVRI MA GDOT

27
My Top 5 Dividend Stocks For Young Investors: Revisited

2h seekingalpha
When I wrote the original piece a year ago, I picked AAPL, NVDA, NKE, DIS, and T.
V NKE AAPL MA MSFT SBUX NVDA

2
Mastercard, Worldplay Join Forces to Drive Digital Payment

23h zacks
Mastercard Incorporated (MA - Free Report) and Worldpay, Inc. recently announced intentions to collaborate on expanding digital payment acceptance options and increasing the security and convenience level of customers. Through this tie-up, both companies will engage in boosting payment acceptance options for U.K.-based customers and retailers. The alliance will allow the entities to leverage account-to-account payments technology with Mastercard's 'Pay by Bank' application, created by the parent company’s Vocalink business.
EVRI MA WEX GDOT

9
Mastercard: Invest In Cashless Transactions

2018-07-16 seekingalpha
In the face of geopolitical, economic and technological tensions, Mastercard Inc. (NYSE:MA) has two major tailwinds that continue to fuel the company and keep the stock price moving forward. These tailwinds are: the world continues to deviate away from cash in favour of digital forms of transactions, and a huge growth in global middle class population throughout the world.
V MA

10
Is Visa Stock Really a Bulletproof Investment?

2018-07-16 investorplace
Visa’s (NYSE:V) stock chart is almost boring to look at. Shares have been steadily climbing for several years now; there are little to no significant downtrends evident in the chart’s five-year view. And in 2018 thus far, V stock has gained over 22% — more than four times better than the broader market.
V MA

97
March To Freedom Fund Mid-Year Review

2018-07-13 seekingalpha
The first half of 2018 is already over, so it is time to look back at how our portfolio performed, the purchases we made and to check our income growth.
SOJA LMT GIS XOM O.PRF TWX OPRF CVS ABT NKE HON AAPL ABBV DIS ABT VTR HON SO GILD O MA TWC RB CMI TGT V AFL PEP JNJ CVX DG MSFT SBUX ABBV QCOM

9
Mastercard, Diebold Team Up to Offer Smart Digital Services

2018-07-13 zacks
Mastercard Incorporated (MA - Free Report) recently entered into a collaboration with Diebold Nixdorf, Incorporated (DBD) for delivering industry-defining, managed solution for banking as well as retail sectors. The tie-up would combine Mastercard's efficiency in providing state-of-the-art processing services and an extensive global network capability on the back-end with Diebold Nixdorf's proficiency in omni-channel innovation and consumer transactions on the front-end.
V MA WEX GDOT

14
Buy PayPal Because It's Headed The Right Way

2018-07-13 seekingalpha
PayPal’s (PYPL) $2.2 billion acquisition of iZettle is its largest but the most calculated one. The aim is simple, to increase PayPal’s presence in physical outlets. iZettle’s card readers allow anyone to receive card payments, while its point of sale system manages payment processing, sales tracking, and product management. That’s right, instead of just trying to beat traditional card-payment processors in online platforms, PayPal will make the competition more relevant by playing both the online and in-store payment processing market, and it gets better along with the integration of sales and product management tools that’s essential for the small and medium businesses.
V SQ MA

116
China Blinked - Cramer's Mad Money (7/12/18)

2018-07-13 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, July 12.
APC FB CHDN MA NFLX AXP GOOG VICI SAGE V AMZN JNJ AAPL TSLA KSS PENN AEUA BYD

31
Oakmark Fund: Second Quarter 2018

2018-07-13 seekingalpha
Average Annual Total Returns (06/30/18) Since Inception (08/05/91) 12.84% 10–year 12.48% 5–year 13.07% 1–year 13.46% 3–month 2.13% Gross Expense Ratio as of 09/30/17 was 0.90% Net Expense Ratio as of 09/30/17 was 0.86%
MGM APC FB BMYMP AAL ADP MA NFLX HOG IT V AFL ADPVV AAPL HLT AEUA BMY

127
Which Stocks Are Immune To Trade War? - Cramer's Mad Money (7/11/18)

2018-07-12 seekingalpha
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, July 11.
PFPT MRVL STZ.B SQ CAT XOM PANW MA PYPL UTX STZ VMW CGC TWMJF V HON CVX WEED BA MMM

115
Oakmark Equity And Income Fund: Second Quarter 2018

2018-07-11 seekingalpha
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM C.WSA DOV.WI NOV TEL CVS FNF BAC C.WS.B CHTR APY.WI GM.WS.A FNFV C.WS.A GM.WS.B GM.WS.C C.PRP DOV C.PRU GM ORCL C.PRS LBRDB BAC C C.PRL AAL C.PRJ C.PRK BHGE COMM MA ARNC C.PRG TWC LBRDK C.PRC BHI C.PRPCL CGBBW OCLCF JLL LBRDA FL APY GM.WSB UNH

37
Oakmark Global Fund: Second Quarter 2018

2018-07-11 seekingalpha
The Oakmark Global Fund’s three-month return declined 0.3%, compared to a 1.7% return for the MSCI World Index during the period and the Lipper Global Fund Index’s gain of 0.4%.
DGLD LBTY NOV UAA TEL GOOG IPG CS CHTR UGLD LBTYK LILAB GM.WS.A GM.WS.B GM.WS.C GM LUV CNHI LBRDB DSLV VIIX CSSLF VIIZ LBTYB MA LBTYA ARNC DDAIF RB LBRDK UA CSGKF GOOGL LILAK ZIV RBGLY LBRDA USLV TVIX GM.WSB THC TV XIV LILA

40
5 Dividend Mutual Funds for Volatile Markets | InvestorPlace

2018-07-10 investorplace
Unless you invested in select areas of the markets — like the Internet giants and cloud operators — it’s been challenging year. Note that the return on the S&P 500 has been a mere 3%.
HD PFZ MTSI JNJ AAPL MA NYTAB 500680 PFE PFIZER MCD MMM

263
18 Stocks That Could Be Takeover Targets | InvestorPlace

2018-07-10 investorplace
M&A activity has been big part of the global market for the past few years now, and that’s likely to continue. Tax reform has freed up more cash and made potential targets more accretive. The economy is humming along. And in a few key sectors — consumer goods and media come to mind — there’s an obvious logic behind consolidation.
TXN GRA TWX MS.PRE MS.PRF MS.PRG MS.PRA WMT WFM ERIC SFM HON AVGO CSCO NOK MS MXIM AA FOX GD SQ LGF HAIN UTX ARNC TWC HRL MAT MS.PRI GOOGL ERI MS.PRK PENN MSFT LVS BA QCOM BB FOXA GCP XLNX LMT MGM FB MTSI PNK RAD CPB PYPL AVAV GOOG FIZZ KR AMCX 6723 KO RNECY MSGN CIEN DIS HON WYNN CMCSA RNECF MA COL BMRN SNY RHT TGT V HAS PEP DPS T ADI KHC LGF.A LGF.B

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to MA / MasterCard Incorporated on message board site Silicon Investor.

Buy and Sell Signals, and Other Market Perspectives smallcap risk reward potential
TNRG Tianrong Building Materials Mainstream Politics and Economics
International Automated Systems Technology Stocks u0026 Market Talk With Don Wolanchuk
Marijuana Stocks Amazon.com, Inc. (AMZN)
The Zenyatta Information Board Canu0027t Beat Amazon!
CUSIP: 57636Q104